Friday, March 15, 2013
Oculus Innovative Sciences Inc., of Petaluma, Calif., completed a 112-day follow-up period in a trial of Microcyn Technology-based hydrogel for hypertrophic or keloid scars in 40 patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.